HCW Biologics (NASDAQ:HCWB – Get Rating) and MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and target prices for HCW Biologics and MoonLake Immunotherapeutics, as reported by MarketBeat.com.

HCW Biologics currently has a consensus price target of $6.00, suggesting a potential upside of 192.68%. MoonLake Immunotherapeutics has a consensus price target of $20.33, suggesting a potential upside of 106.85%. Given HCW Biologics' higher probable upside, research analysts clearly believe HCW Biologics is more favorable than MoonLake Immunotherapeutics.

Profitability

Institutional & Insider Ownership

1.6% of HCW Biologics shares are held by institutional investors. 44.0% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

HCW Biologics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Earnings & Valuation

This table compares HCW Biologics and MoonLake Immunotherapeutics' gross revenue, earnings per share and valuation.

MoonLake Immunotherapeutics has lower revenue, but higher earnings than HCW Biologics.

Summary

MoonLake Immunotherapeutics beats HCW Biologics on 5 of the 9 factors compared between the two stocks.

About HCW Biologics

(Get Rating)

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

About MoonLake Immunotherapeutics

(Get Rating)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.